
How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?
This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discusses the evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma, focusing on the combination of tafasitamab and lenalidomide. He highlights how this immunotherapy regimen, targeting CD19, has shown promising efficacy, with a high overall response rate and sustained complete…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.